
    
      All patients enrolled will be submitted to laparoscopic cholecystectomy. The primary aim of
      the trial will be to assess the role of prophylactic i.v. infusion of ampicillin-sulbactam,
      ciprofloxacin, and placebo to reduce the rate of surgical site infection.
    
  